How old do you have to be to take Mounjaro?

What the UK licence actually specifies about age

The MHRA granted Mounjaro its UK marketing authorisation for adults, the SmPC (Summary of Product Characteristics) defines the eligible population as adults aged 18 and over. That boundary is set by the licence, not by individual prescribers or pharmacies. It applies whether Mounjaro is being considered for weight management or for type 2 diabetes.

This matters because a prescriber can occasionally use a medicine outside its licensed indication in specific circumstances, but prescribing a POM to a population it is not licensed for carries a high regulatory and clinical bar. In practice, no reputable UK prescriber issues Mounjaro to under-18s for weight management. The NHS medicines page for tirzepatide is explicit on this point.

If you are researching this question on behalf of a teenager, the appropriate first step is a conversation with their GP. Paediatric weight management follows a different clinical pathway entirely, led by specialist services rather than prescribing medicines licensed for adults.

Worth checking: the GPhC register at pharmacyregulation.org/registers confirms whether any online pharmacy offering you a service is legitimately registered, a reliable 30-second habit before sharing any health information online.

Why the trial evidence draws the line at 18

The SURMOUNT clinical programme (the phase-3 trials that underpinned Mounjaro's weight-management licence) enrolled adults. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 participants with obesity or overweight and at least one weight-related condition; all were adults. The trial data regulators used to assess safety, tolerability and efficacy therefore reflects an adult-only population.

Extending a licence to younger age groups requires its own paediatric studies, its own safety data, and a separate regulatory review. As of summer 2026, no such licence extension exists for Mounjaro in the UK. This is not unusual: most weight-management medicines follow the same pattern, reaching adults first while paediatric evidence is gathered separately, if at all.

The practical upshot is that there is no clinical evidence base a UK prescriber could draw on to justify a tirzepatide prescription for a 15- or 16-year-old, even where obesity is clinically significant. Questions about weight thresholds for Mounjaro eligibility are therefore only relevant once the age threshold is met.

What this means at the consultation stage

When someone applies through a regulated service, age is verified early. At nume, every application is reviewed by a GPhC-registered Independent Prescriber (a named clinician, not automated software) and photo-ID identity verification is part of the process. If an applicant is under 18, the consultation does not proceed to prescribing.

This is one reason the consultation-first model matters for a prescription-only medicine. An online listing is not the same as a prescription; obtaining tirzepatide requires a prescriber to assess suitability, and age is a hard stop. Our Mounjaro treatment page covers the full eligibility picture for adults who do qualify.

For adults who are 18 or over and want to understand the broader eligibility criteria (including BMI requirements and qualifying conditions) the question of what weight you need to be is covered separately. Separately, if you are curious about how the medicine works once treatment is underway, how Mounjaro is taken walks through the injection process in plain terms.

Are there any weight-management options for under-18s in the UK?

This page is focused on Mounjaro specifically. The short answer for under-18s is that the licensed adult weight-management medicines (tirzepatide and semaglutide) are not available to them through any legitimate UK prescriber for this indication. Paediatric obesity management is handled through NHS specialist children's services, which use behavioural, dietary and, in some cases, surgical pathways appropriate to the age group.

If you are 18 or over and are considering your options, it is worth knowing that weight-loss treatment options differ meaningfully by mechanism and eligibility. Cost is a common question too, the Eli Lilly price increase in the UK changed the private market significantly from September 2025, and understanding what private treatment costs as a whole is useful context before starting.

Adults who do meet the criteria and want to take the next step can check their eligibility through a free consultation with our prescribers.